{"analyses":[{"groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8577","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)","statisticalMethod":"ANOVA"},{"groupIds":["OG003","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7238","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)","statisticalMethod":"ANOVA"},{"groupIds":["OG003","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5923","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)","statisticalMethod":"ANOVA"},{"groupIds":["OG004","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7634","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)","statisticalMethod":"ANOVA"},{"groupIds":["OG004","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5749","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)","statisticalMethod":"ANOVA"},{"groupIds":["OG005","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6877","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"comment":"A standard deviation was not calculated for a single participant.","groupId":"OG000","spread":"NA","value":"208"},{"comment":"A standard deviation was not calculated for a single participant.","groupId":"OG001","spread":"NA","value":"322"},{"comment":"A standard deviation was not calculated for a single participant.","groupId":"OG002","spread":"NA","value":"1380"},{"groupId":"OG003","spread":"301","value":"1080"},{"groupId":"OG004","spread":"1630","value":"2180"},{"groupId":"OG005","spread":"1890","value":"3010"},{"groupId":"OG006","spread":"1480","value":"4350"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"57"},{"groupId":"OG006","value":"13"}],"units":"Participants"}],"description":"AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.","dispersionType":"Standard Deviation","groups":[{"description":"Participants self-administered oral pemigatinib 1 milligram (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG000","title":"Part 1: Intermittent Pemigatinib 1 mg QD"},{"description":"Participants self-administered oral pemigatinib 2 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG001","title":"Part 1: Intermittent Pemigatinib 2 mg QD"},{"description":"Participants self-administered oral pemigatinib 4 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG002","title":"Part 1: Intermittent Pemigatinib 4 mg QD"},{"description":"Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG003","title":"Part 1: Intermittent Pemigatinib 6 mg QD"},{"description":"Participants self-administered intermittent or continuous oral pemigatinib 9 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG004","title":"Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD"},{"description":"Participants self-administered intermittent or continuous oral pemigatinib 13.5 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG005","title":"Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD"},{"description":"Participants self-administered intermittent or continuous oral pemigatinib 20 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG006","title":"Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD"}],"paramType":"MEAN","populationDescription":"PK/PD Population. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14","title":"Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}